Today Marengo Therapeutics announced?a clinical study collaboration with Gilead Sciences to evaluate Marengo’s Invikafusp alfa (STAR0602) and Gilead’s Trodelvy? in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers.? ? The collaboration will evaluate the combination of Marengo’s first-in-class TCR Vb selective dual T cell agonist, STAR0602 (Invikafusp alfa), with Trodelvy (sacituzumab govitecan-hziy) Gilead’s Trop-2 directed ADC in a new multi-center Phase I/II clinical study (START-002). This innovative combination approach will leverage two unique modalities to target and potentially eradicate cancer cells. Read our press release to learn more:?https://lnkd.in/e6kX7Nhb
Marengo Therapeutics
生物技术研究
Cambridge,MA 4,774 位关注者
A new frontier in the fight against cancer– the right activation of the right immune cells
关于我们
Marengo Therapeutics, a clinical stage biotech company, is pioneering an entirely new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay. For more information visit our website (https://www.marengotx.com)
- 网站
-
https://www.marengotx.com
Marengo Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge,MA
- 类型
- 私人持股
- 领域
- Immuno-oncology、Oncology、T cell biology、Immunology、Drug Development和Biologics
地点
-
主要
840 Memorial Drive
4th Floor
US,MA,Cambridge,02139
Marengo Therapeutics员工
-
Madan Katragadda Ph.D., MBA
VP, Antibody Technologies and CMC at Marengo Therapeutics
-
Claire Coleman
Vice President Program Management at Marengo Pharmaceuticals
-
Zhen Su, MD MBA
Physician Scientist, Entrepreneur and CEO at Marengo Therapeutics
-
Kevin Chin
Chief Medical Officer, Marengo Therapeutics
动态
-
During our all-hands today we said “Cheers to the years!” and honored Marengoers recently marking milestone anniversaries.?Huge Congratulations to Wei Huang , Jian Tang, Jonathan Hsu and Irene Kam, who have been with Marengo for 7 years; and Roya Servattalab, Yenong Zhou and Jessica Lowry, who have been with Marengo for 6 years, respectively. ? At Marengo we're united in our journey, and every milestone is a testament to our collective strength and dedication. Happy anniversary to our incredible team members!
-
It's official! ??Marengo Therapeutics has been featured on Fortune’s "2024 Best Small & Medium Workplaces in BioPharma" list! ?? #greatplacetowork #BestWorkplacesBioPharma #GPTWcertified
-
Fall is here and September has started off with a bang – today we are welcoming Camelia Raize and Yanfeng Zhou to the Marengo team. We are thrilled to have you with us! ? ?Check out our current open roles: https://lnkd.in/eQCzHw7z
-
Please welcome Srinjoy Chakraborti, PhD, who joined Marengo earlier this July. We are ecstatic to have you with us! ? Check out our current open roles: https://lnkd.in/eQCzHw7z
-
Earlier this month, Marengo’s research team embarked on a helpful offsite team-building event, graciously hosted by Claria Partners . During this event, we delved into our Insights Discovery results. The Insights Discovery tool uses a 4-color model to help people understand their style, their strengths, and the value they bring to the team. ? As the final group at Marengo to undergo this process, our scientists were eager to uncover their results and compare them with those of their colleagues. It came as no surprise that "cool blue" emerged prominently among our team. ? Our heartfelt thanks to Claria Partners for orchestrating such a valuable and insightful event. Many of our team members continue to reflect on the profound insights gained.
-
This summer, we’ve been extremely fortunate to have Keana Ramos Baptista on our team. Keana, who is about to enter her junior year at Boston University, has spent the past few months assisting the Marengo team in the office and the lab. Her contributions have made her an invaluable member of our People & Culture team. We met Keana through Project Onramp , a wonderful program by Life Science Cares Boston. We are truly grateful for the dedication and enthusiasm she has brought to her internship. We are excited to see all the amazing things Keana will accomplish in the future and wish her the very best. Learn more about the program here: https://projectonramp.us
-
Attending DIA (Drug Information Association)'s Global Annual Meeting in San Diego? Join Marengo's Chief Development Officer Ke Liu , MD, PhD for their panel session to interpret FDA guidance, discuss trends, and share their own experiences for study design in cell and gene therapy trials.
-
Wonderful discussion on expediting the #platform to #pipeline journey with Leslie J Williams HC Bioscience, Inc., Rachel W. Humphrey, MD Normunity, Geoffrey McDonough Generation Bio, Mittul Mehta TEVOGEN BIO, Zhen Su, MD MBA Marengo Therapeutics at #longwoodhealthcareleaders Longwood Fund
-
What an honor to host Brad Loncar (BiotechTV) on site at Marengo Therapeutics and chat about our recent $1.2B partnership with Ipsen focused on our next generation Precision T-cell engager approach to bring more targeted IO therapeutics to "COLD" tumor. Let's to it together as One Team!
?????????????? ????????: Marengo Therapeutics' CEO Zhen Su, MD MBA on the expansion of a partnership with Ipsen to activate T-cells against cold tumors. He describes how to succeed against cold tumors where T-cells are not in abundance to begin with, you have to activate and then drive them to the tumor. Full video: https://lnkd.in/gyC4EEY9 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent